Artelo Biosciences, Inc. (ARTL)
Company Description
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system.
Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.
Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.
Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
| Country | United States |
| Founded | 2011 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Employees | 4 |
Contact Details
Address: 505 Lomas Santa Fe Solana Beach, CA 92075 United States | |
| Phone | 858 925 7049 |
| Website | artelobio.com |
Stock Details
| Ticker Symbol | ARTL |
| Exchange | NASDAQ |
| Fiscal Year | September - August |
| Reporting Currency | US Dollars |
| CIK Code | 1621221 |
Key Executives
| Name | Position |
|---|---|
| Gregory D. Gorgas M.B.A. | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Andrew Yates Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Steven D. Reich | Chief Medical Officer |
| Jason H. Baybutt | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Apr 7, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2022 | 10-KT | Transition reports [Rule 13a-10 or 15d-10] |
| Mar 16, 2022 | 8-K | Current report |
| Mar 9, 2022 | 8-K | Current report |
| Feb 23, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Feb 4, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Jan 12, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Dec 7, 2021 | 8-K | Current report |
| View All SEC Filings | ||